Philadelphia, PA - Using a strategy that takes the classic "house-call" to new extremes, a traveling medical team made up of cardiothoracic surgeons, anesthesiologists, and nurses is bringing a ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...

From the Laboratory of Surgical Research, Harvard Medical School, and the Department of Surgery, Children's Hospital, Boston. Select the format you want to export the citation of this publication.

A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm babies. Findings from the ...

Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...

None of these approaches has shown clear benefits in short- and long-range outcomes.

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...